NCT07029828View on ClinicalTrials.gov

A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.

PHASE3RecruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

September 10, 2025

Primary Completion Date

June 26, 2030

Study Completion Date

June 26, 2030

Conditions
Severe Alopecia Areata
Interventions
DRUG

Ritlecitinib higher dose

Study intervention will be provided as oral capsules centrally by the sponsor in HDPE bottles.

DRUG

Ritlecitinib lower dose

Study intervention will be provided as oral capsules centrally by the sponsor in HDPE bottles.

Trial Locations (4)

33156

RECRUITING

Pediatric Skin Research, Miami

46250

RECRUITING

Dawes Fretzin Clinical Research Group, LLC, Indianapolis

78218

RECRUITING

Texas Dermatology and Laser Specialists, San Antonio

97210

RECRUITING

Northwest Dermatology Institute, Portland

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT07029828 - A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata. | Biotech Hunter | Biotech Hunter